On Oct 17, major Wall Street analysts update their ratings for $Abbott Laboratories (ABT.US)$, with price targets ranging from $125 to $146.
Goldman Sachs analyst David Roman maintains with a buy rating.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and maintains the target price at $135.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $133.
Citi analyst Joanne Wuensch maintains with a buy rating.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $143 to $146.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Abbott's slight surpassing of sales and EPS estimates reinforces the belief in the company's capacity to maintain double-digit MedTech sales growth in the coming period, alongside high single-digit growth in total sales. Analysts consider the enduring growth trajectory of Abbott's MedTech business to be undervalued. Furthermore, Abbott is recognized for offering a high-quality opportunity for high single-digit to low double-digit sales growth.
Following the Q3 results, Abbott is considered to be well-positioned to handle any competition from pulsed field ablation, and the potential for leadless pacing is expected to possibly spur growth in cardiac rhythm management to exceed 3%. While operational performance has been strong, it's assessed that current market expectations are already reflective of this, and the company's valuation is deemed reasonable when compared to its peers.
While acknowledging Abbott's positive trajectory post the third-quarter report, analysts continue to search for indications of enduring operating margin growth following the conclusion of the Testing phase.
Abbott's third-quarter sales exceeded consensus expectations, bolstered by a strong showing in the MedTech segment and revenue from COVID tests. The company also maintained its organic growth guidance for FY24 and raised the mid-point of its EPS forecast. Despite these positive developments, a cautious stance is maintained due to valuation and pending litigation concerns, though the company's performance is seen in a favorable light.
Abbott management indicated optimism about the company's potential for sustained high-single-digit revenue growth and double-digit earnings growth. Specifically, the CEO's comments suggested that high-single digit revenue and 10% earnings per share growth are seen as a feasible baseline. With numerous new offerings in the rapidly expanding Diabetes Care and Structural Heart markets, Abbott's comprehensive medical device portfolio appears poised for superior growth within the medical technology sector.
Here are the latest investment ratings and price targets for $Abbott Laboratories (ABT.US)$ from 14 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月17日，多家華爾街大行更新了$雅培 (ABT.US)$的評級，目標價介於125美元至146美元。
高盛集團分析師David Roman維持買入評級。
摩根大通分析師Robbie Marcus維持買入評級，維持目標價135美元。
美銀證券分析師Travis Steed維持買入評級，維持目標價133美元。
花旗分析師Joanne Wuensch維持買入評級。
瑞士銀行分析師Danielle Antalffy維持買入評級，並將目標價從143美元上調至146美元。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
在銷售和每股收益超過預期的輕微優勢之後，加強了對該公司能夠在未來時期保持雙位數醫療科技銷售增長以及總銷售高位數增長的信心，分析師認爲Abbott的醫療科技業務的持續增長軌跡被低估。此外，Abbott因爲爲高位數至低雙位數銷售增長提供了高質量的機會而備受認可。
在第三季度的成果發佈之後，Abbott被認爲已經做好了處理脈衝場消融帶來的任何競爭的準備，並且無線起搏的潛力有望刺激心臟節律管理的增長超過3%。儘管運營業績強勁，但對於目前市場預期已經反映了這一點，並且在與同行相比，公司的估值被認爲是合理的。
在承認Abbott在第三季度報告後的正面發展軌跡的同時，分析師繼續尋找測試階段結束後持續營業利潤率增長的跡象。
Abbott第三季度的銷售超出共識預期，得益於醫療科技業務和來自COVID測試的收入。該公司還維持了FY24的有機增長指引，並提高了每股收益預期的中間點。儘管出現了這些積極的發展，但由於估值和未決訴訟問題，仍持謹慎態度，不過公司的業績被認爲是積極的。
Abbott管理層對公司持續高位數收入增長和雙位數盈利增長的潛力表現出樂觀態度。具體來說，首席執行官的評論表明，高位數收入增長和10%的每股收益增長被視爲可行的基準。在不斷擴大的糖尿病護理和結構性心臟市場中推出衆多新產品之後，Abbott的全面醫療器械產品系列似乎準備好在醫療科技領域取得卓越增長。
以下爲今日14位分析師對$雅培 (ABT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
